What makes Prilenia’s PREVAiLS trial different from past ALS failures
FDA clears Prilenia’s PREVAiLS ALS trial. Can pridopidine validate neuroprotection and shift the treatment paradigm? Read the full analysis here.
Pharma & Biotech
Pharma & Biotech
Can Pfizer reposition TUKYSA as a first-line maintenance option after HER2CLIMB-05?
Pfizer’s tucatinib combo extends progression-free survival in HER2+ metastatic breast cancer. Find out what HER2CLIMB-05 means for frontline maintenance therapy.
Pharma & Biotech
Can IDE574 reshape breast and lung cancer treatment by targeting KAT6 and KAT7?
IDEAYA Biosciences files IND for IDE574, a KAT6/7 inhibitor for breast and lung cancer. Learn how this new class may change epigenetic treatment strategies.
Pharma & Biotech
Can Ascletis’ denifanstat reshape acne treatment by targeting fatty acid synthesis?
Ascletis' acne drug denifanstat advances with NDA acceptance in China. Explore how FASN targeting could disrupt acne care and redefine systemic treatments.
Pharma & Biotech
Novo Nordisk finalizes $5.2bn Akero deal to expand in advanced MASH care
Novo Nordisk has acquired Akero Therapeutics for up to $5.2 billion to advance efruxifermin, its Phase 3 MASH asset. Find out what this means for liver care.
Pharma & Biotech
Could Novartis change the ITP playbook with just four doses of ianalumab?
Can four doses replace chronic ITP therapy? Find out how Novartis’ ianalumab performed in the VAYHIT2 trial and what it could mean for autoimmune care.
Pharma & Biotech
MajesTEC-3 results put Johnson & Johnson’s bispecific combo at center of myeloma care debate
TECVAYLI and DARZALEX FASPRO show major survival benefits in second-line multiple myeloma. Find out what the MajesTEC-3 trial means for clinical practice.
Pharma & Biotech
Is Eli Lilly’s Jaypirca now the most compelling single-agent therapy in untreated CLL?
Lilly’s Jaypirca reduced progression risk by 80% in frontline CLL. Explore what this changes for therapy sequencing, safety, and BTK inhibitor strategy.
Pharma & Biotech
Eli Lilly’s $6bn API plant in Alabama signals new era in U.S. peptide drug manufacturing
Eli Lilly’s $6B Alabama facility will manufacture orforglipron and peptide APIs. Explore how this reshoring move could transform U.S. drug manufacturing.
Pharma & Biotech
Eli Lilly targets first-line CLL with Jaypirca as BRUIN CLL-314 trends toward PFS benefit
Lilly’s Jaypirca met its Phase 3 target in CLL, matching Imbruvica on response rate and showing superior safety. Could this rewire frontline BTK therapy?